The Evidence Speaks (January 2023)
The first Evidence Speaks of 2023 features mask mandate effectiveness, client preferences for iOAT delivery, and patient-reported outcomes following hysterectomy
Read MoreAugust 3, 2022
The first Evidence Speaks of 2023 features mask mandate effectiveness, client preferences for iOAT delivery, and patient-reported outcomes following hysterectomy
Read More
CHÉOS Scientists are leading three of the projects funded in this round, plus a further eleven projects are supported by CHÉOS Scientists as co-investigators.
Read More
How diverse patient perspectives can be used to inform future clinical research and practice
Read More
Drs. Eugenia Oviedo-Joekes and Anne Gadermann are among the 156 new and renewed Canada Research Chairs
Read More
After more than 20 years at CHÉOS, Dr. Peter Dodek is set to retire at the end of June. Join us in learning about his fascinating career as a clinician-scientist
Read More
CHÉOS Scientist Dr. Eugenia Oviedo-Joekes is a co-author on the first-ever clinical guidelines for use of injectable opioid agonist treatment for opioid use disorder.
Read More
PORTIA is the latest study in a long-term program of research that is developing evidence-based overdose prevention strategies and helping address the opioid crisis
Read More
The 27th edition summarizes some of the latest research from CHÉOS Scientists, including incarceration and homelessness, adverse events, and societal values related to drug funding.
Read More
Governments of Canada and British Columbia designate funds to expand access to effective and appropriate treatment options for substance use disorder, Foundry among recipients
Read More
Dr. Aslam Anis was recently awarded a Distinguished Achievement Award from the UBC Faculty of Medicine
Read More